Abstract
A series of novel 1,2,3-triazole-chalcone hybrid compounds were designed and synthesized from thymol. The structural identity of the synthesized products 5a-h was unequivocally confirmed by spectroscopic techniques, including 1H and 13C NMR spectroscopy, and high-resolution mass spectrometry (HRMS), and SC-XRD for 5b. The in vitro anticancer activity of the synthesized compounds was evaluated against a panel of four human cancer cell lines: fibrosarcoma (HT-1080), lung adenocarcinoma (A-549), and breast adenocarcinoma (MCF-7 and MDA-MB-231). Notably, most of the 1,2,3-triazole-chalcone hybrids (5a-h) displayed promising cell growth inhibition with IC50 values ranging from 4.61 to 50 μM. Furthermore, compounds 5a and 5b, bearing a 1-phenyl-1,2,3-triazole moiety and a 1-cyano-1,2,3-triazole moiety, respectively, exhibited particularly significant antiproliferative activity against HT-1080 cells. These compounds displayed impressive IC50 values of approximately 4.61 μM and 9.08 μM, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
